A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan to End Public Aid for COVID Drugs at March-End
February 21, 2024
-
REGULATORY Xocova, Astellas’s Gastric Cancer Med Up for PAFSC Review on March 4; Pfizer’s Bispecific, RSV Jab Also on Agenda
February 20, 2024
-
BUSINESS Gilead Japan Ramping Up Sales Force with Trodelvy Now under Review
February 20, 2024
-
BUSINESS Active Pharma Hid Botched API Production, Source Reveals Details of Violations
February 19, 2024
-
BUSINESS Cancer Specialist BeiGene Set to Enter Japan Market as Early as This Year
February 16, 2024
-
BUSINESS GSK Japan Nets 11% Sales Rise in 2023, Sees 6% CAGR through 2026: President
February 15, 2024
-
REGULATORY Japan to Announce New Drug Prices on March 5
February 15, 2024
-
REGULATORY Chuikyo Issues 2024 Reform Recommendation; 1,000 Yen Premium Set for Inpatient Biosimilar Use
February 14, 2024
-
REGULATORY Japan Approves Jardiance for CKD, Label Expansion for Opdivo and More
February 13, 2024
-
BUSINESS Medac Poised to Cement Japan Foothold in RA, Eyes Rare Disease Launch Too: CEO
February 9, 2024
-
BUSINESS Mounjaro Logs 5.6 Billion Yen in Q3 YTD despite Curbed Shipments: Mitsubishi
February 8, 2024
-
REGULATORY Generic Panel to Issue Report in Spring-Summer to Drive Manufacturing Efficiency towards Stable Supplies: Official
February 8, 2024
-
REGULATORY Legal Changes on Horizon for GMP Inspection Authorities, Other Regulation Panel Topics?
February 7, 2024
-
BUSINESS 2,000 Patients Receiving Leqembi in US, 4 Times the Number on Wait List: Eisai
February 7, 2024
-
REGULATORY AMED Needs More Manpower to Fulfill Its Role as Funding Agency: President
February 6, 2024
-
BUSINESS Sumitomo to Reinforce Restructuring to Fight Deficit, First in North America: President
February 6, 2024
-
REGULATORY Truvada Clears Preliminary Review for PrEP Use, but Coverage Not Granted
February 6, 2024
-
REGULATORY Will Truvada Win Health Coverage as Japan’s First Drug for HIV Prevention?
February 5, 2024
-
BUSINESS Chugai’s 2023 Earnings Slip as Ronapreve Wanes, but Sales Still Top 1 Trillion Yen
February 2, 2024
-
REGULATORY Japan to Introduce Fee Premium for Inpatient Biosimilar Use, Covering 13 APIs
February 1, 2024
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…